We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serodiagnostic Test Developed for Human Leptospirosis

By LabMedica International staff writers
Posted on 11 Jul 2013
Print article
Image: Vertical Flow Rapid Diagnostic Test for Leptospirosis (Photo courtesy of Pasteur Institute of New Caledonia).
Image: Vertical Flow Rapid Diagnostic Test for Leptospirosis (Photo courtesy of Pasteur Institute of New Caledonia).
A vertical flow diagnostic test has been developed for the serodiagnosis of human leptospirosis, which is difficult to diagnose because of nonspecific symptoms and concurrent other endemic febrile diseases.

Scientists at the Pasteur Institute of New Caledonia (Noumea, New Caledonia) working with their colleagues at the Pasteur Institute (Paris, France) tested 187 confirmed leptospirosis cases sera. There were 120 from New Caledonia, 38 from mainland France, 29 from French West Indies. Whole killed Leptospira fainei cells were used as the antigen for the test line and purified human immunoglobulin M (IgM) as the control line. The mobile phase was made of gold particles conjugated with goat anti-human IgM. The Microscopic Agglutination Test (MAT) was used as the gold standard with a cut-off titer of equal to or greater than 1:400.

Out of the 187 gold standard positive sera tested, 168 were RDT positive, including 15 RDT with a test line intensity graded as weak. Out of the 221 MAT-negative sera tested, 207 were RDT negative. All 14 RDT positive sera were graded weak and originated from nine healthy blood donors and five patients positive for anti-dengue virus IgM. The RDT sensitivity was 89.8% and the specificity 93.7%. This RDT had satisfactory reproducibility, repeatability, thermal tolerance, and shelf life. The comparison with MAT evidenced the earliness of the RDT to detect seroconversion. The Vertical Flow RDT developed displayed good diagnostic performances when compared with a lateral flow RDT (Leptocheck, Zephyr Biomedicals; Goa, India).

The authors concluded that because leptospirosis is endemic in New Caledonia and French West Indies, they considered both a MAT titer of 1:400 as a gold standard and a 1/400 dilution of the serum for the Vertical Flow RDT for evaluation. They wrote that it is highly probable that the use of a lower dilution of 1/200 or 1/100 would result in both an increased sensitivity and a decreased specificity. The use of the Vertical Flow RDT as an initial screen for leptospiral infections would still allow facilitating the difficult differential diagnosis of leptospirosis. The study was published on June 27, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Pasteur Institute of New Caledonia
Pasteur Institute
Zephyr Biomedicals


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.